Christopher H. Cabell
Pfizer (United States)(US)New York Times(US)Arena Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Infective Endocarditis Diagnosis and Management, Antimicrobial Resistance in Staphylococcus, Streptococcal Infections and Treatments, Cardiac Valve Diseases and Treatments, Bacterial Identification and Susceptibility Testing
Most-Cited Works
- → Prevention of Infective Endocarditis(2007)2,785 cited
- → Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus(2006)1,454 cited
- → Staphylococcus aureus Endocarditis(2005)1,160 cited
- → Relation of frequency and severity of mitral regurgitation to survival among patients with left ventricular systolic dysfunction and heart failure(2003)686 cited
- → Clinical Identifiers of Complicated Staphylococcus aureus Bacteremia(2003)640 cited
- → Changing Patient Characteristics and the Effect on Mortality in Endocarditis(2002)546 cited